Yulia Mordashova

Hirschhorn, RP, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Exploring longitudinal relationships among Alzheimer's disease biomarkers.

Exploring longitudinal relationships among Alzheimer's disease biomarkers.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: January 29, 2026

Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.

Predicting onset of symptomatic Alzheimer's disease with plasma p-tau217 clocks.

Journal: Nature medicine

Published: July 06, 2025

Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks.

Timing of Changes in Alzheimer's Disease Plasma Biomarkers as Assessed by Amyloid and Tau PET Clocks.

Journal: Annals of neurology

Published: February 18, 2025

Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks.

Timing of changes in Alzheimer's disease plasma biomarkers as assessed by amyloid and tau PET clocks.

Journal: medRxiv : the preprint server for health sciences

Published: November 22, 2024

Statistical Tutorial for Cut-Point Determination in Immunogenicity Studies.

Statistical Tutorial for Cut-Point Determination in Immunogenicity Studies.

Journal: Pharmaceutical statistics

Published: July 08, 2024

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.

Journal: medRxiv : the preprint server for health sciences

Published: July 01, 2024

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.

Head-to-head comparison of leading blood tests for Alzheimer's disease pathology.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: June 06, 2024

Neutralizing RGMa with Elezanumab Promotes Cerebroprotection and Recovery in Rabbit Middle Cerebral Artery Occlusion.

Neutralizing RGMa with Elezanumab Promotes Cerebroprotection and Recovery in Rabbit Middle Cerebral Artery Occlusion.

Journal: Translational stroke research

Published: March 01, 2023

Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity.

Comparative analytical performance of multiple plasma Aβ42 and Aβ40 assays and their ability to predict positron emission tomography amyloid positivity.

Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association

Published: January 03, 2022

Tau in the brain interstitial fluid is fragmented and seeding-competent.

Tau in the brain interstitial fluid is fragmented and seeding-competent.

Journal: Neurobiology of aging

Published: May 20, 2021

Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates.

Elezanumab, a human anti-RGMa monoclonal antibody, promotes neuroprotection, neuroplasticity, and neurorecovery following a thoracic hemicompression spinal cord injury in non-human primates.

Journal: Neurobiology of disease

Published: January 25, 2021

N368-Tau fragments generated by legumain are detected only in trace amount in the insoluble Tau aggregates isolated from AD brain.

N368-Tau fragments generated by legumain are detected only in trace amount in the insoluble Tau aggregates isolated from AD brain.

Journal: Acta neuropathologica communications

Published: September 13, 2019

Showing 1-12 of 13

Last Updated: 09/26/2026